In the present study, patients with CBF‐AML had higher risk to develop HLA‐I antibodies and PTR, suggesting increased autoimmune responses to HLA‐I in patients with CBF‐AML. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.